MediWound (MDWD) – StreetInsider.com Reports
-
MediWound (MDWD) Tops Q4 EPS by 4c, provides guidance
-
MediWound (MDWD) Announces FDA Acceptance of the Supplement to the NexoBrid BLA
-
MediWound (MDWD) Wins Additional US Dept of Defense Funding to Advance NexoBrid Development for the US Army
-
MediWound (MDWD) Announces Peer-Reviewed Publication of EscharEx Mechanism of Action Study
-
MediWound (MDWD) Tops Q3 EPS by 20c
-
MediWound (MDWD) Appoints Shmulik Hess as COO and Chief Commercial Officer
-
MediWound (MDWD) Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
-
MediWound (MDWD) Collaborates with 3M (MMM) on EscharEx Phase III Study
-
MediWound (MDWD) Deploys NexoBrid for Emergency Supply
-
MediWound (MDWD) Secures Additional U.S. Department of Defense Funding to Advance NexoBrid Development for the U.S. Army
-
MediWound Ltd (MDWD) PT Raised to $26 at H.C. Wainwright
-
MediWound (MDWD) Announces U.S. Commercial Availability of NexoBrid
-
MediWound Ltd (MDWD) PT Lowered to $36 at Oppenheimer on "continued difficult market conditions"
-
MediWound (MDWD) Tops Q2 EPS by 52c, beats revenue
-
MediWound (MDWD) Announces Collaboration with Mölnlycke on EscharEx Phase III Study
-
MediWound (MDWD) Collaborates with MIMEDX (MDXG) on EscharEx Phase III Study
-
MediWound (MDWD) Announces Commercial Launch of NexoBrid in Japan
-
MediWound (MDWD) Reports Positive Results in Its U.S. Phase I/II Study of MW005
-
MediWound (MDWD) Receives Positive Scientific Advice from EMA on EscharEx Phase III Study Design
-
MediWound (MDWD) Misses Q1 EPS by 13c
-
MediWound (MDWD) Announces an Additional $10 Million Award from BARDA
-
MediWound (MDWD) Misses Q4 EPS by 63c
-
MediWound (MDWD) Announces the Appointment of Hani Luxenburg as Chief Financial Officer
-
MediWound (MDWD) Announces $27.5 Million Registered Direct Offering of Ordinary Shares
-
MediWound Ltd (MDWD) PT Raised to $23 at H.C. Wainwright
-
MediWound Ltd (MDWD) PT Raised to $25 at Cowen
-
MediWound (MDWD) Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
-
MediWound's (MDWD) NexoBrid Granted Marketing Approval in Japan
-
Today's most important initiations
-
Maxim Group starts MediWound Ltd (MDWD) at Buy on advanced pipeline in wound care
-
MediWound (MDWD) Strengthens European Presence of NexoBrid
-
MediWound (MDWD) Reports Positive Results in U.S. Phase I/II Study of MW005
-
MediWound (MDWD) Plans 1-for-7 Reverse Stock Split
-
MediWound Ltd (MDWD) PT Lowered to $5.50 at H.C. Wainwright
-
MediWound (MDWD) Misses Q3 EPS by 28c
-
MediWound (MDWD) Forms Strategic Advisory Board
-
MediWound (MDWD) Announces Concurrent Registered Direct, Private Placement Offerings of Common Stock and Warrants for Approximately $30 Million
-
MediWound (MDWD) Announces EMA's Acceptance of Application for Extended Indication for NexoBrid
-
MediWound Ltd (MDWD) PT Raised to $9 at Oppenheimer
-
MediWound (MDWD) Misses Q2 EPS by 3c
-
MediWound (MDWD) Announces FDA Acceptance of BLA for NexoBrid
-
Oppenheimer Assumes MediWound Ltd (MDWD) at Outperform
-
MediWound (MDWD) Reports Positive Initial Data from Phase I/II Study of MW005
-
MediWound (MDWD) Report Positive Results in Phase 2 Pharmacology Study of EscharEx
-
MediWound (MDWD) Appoints Tzvi Palash as COO
-
MediWound Ltd (MDWD) PT Raised to $8 at Wells Fargo
-
MediWound Ltd (MDWD) PT Lowered to $3 at BTIG
-
MediWound (MDWD) Appoints Ofer Gonen as New CEO
-
MediWound (MDWD) Reports Positive Results from US Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
-
MediWound (MDWD) received a Notice of Allowance for its US patent application 16/072,955 titled "DEBRIDING COMPOSITION FOR TREATING WOUNDS" - PatentGrants
Back to MDWD Stock Lookup